Stock Traders Buy High Volume of Put Options on Alder Biopharmaceuticals (ALDR)
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) was the recipient of some unusual options trading on Monday. Stock traders acquired 1,113 put options on the stock. This represents an increase of 1,924% compared to the average daily volume of 55 put options.
ALDR has been the subject of several recent research reports. Mizuho restated a “buy” rating and issued a $29.00 price objective on shares of Alder Biopharmaceuticals in a report on Wednesday, January 31st. Canaccord Genuity set a $22.00 price objective on Alder Biopharmaceuticals and gave the company a “buy” rating in a report on Friday, January 12th. BMO Capital Markets restated a “buy” rating and issued a $22.00 price objective on shares of Alder Biopharmaceuticals in a report on Wednesday, January 3rd. BidaskClub upgraded Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. Finally, Zacks Investment Research downgraded Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $27.93.
Alder Biopharmaceuticals (NASDAQ ALDR) traded up $1.05 on Wednesday, reaching $14.35. The company’s stock had a trading volume of 2,481,426 shares, compared to its average volume of 2,080,000. Alder Biopharmaceuticals has a 52 week low of $8.60 and a 52 week high of $24.65. The stock has a market capitalization of $971.69, a price-to-earnings ratio of -2.67 and a beta of 2.60.
COPYRIGHT VIOLATION NOTICE: This report was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://theolympiareport.com/2018/02/14/stock-traders-buy-high-volume-of-put-options-on-alder-biopharmaceuticals-aldr.html.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.